• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新生儿溶酶体贮积症

Lysosomal storage disorders in the newborn.

作者信息

Staretz-Chacham Orna, Lang Tess C, LaMarca Mary E, Krasnewich Donna, Sidransky Ellen

机构信息

Office of the Clinical Director, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 35, Room 1A213, 35 Convent Dr, MSC 3708, Bethesda, MD 20892-3708, USA.

出版信息

Pediatrics. 2009 Apr;123(4):1191-207. doi: 10.1542/peds.2008-0635.

DOI:10.1542/peds.2008-0635
PMID:19336380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2768319/
Abstract

Lysosomal storage disorders are rare inborn errors of metabolism, with a combined incidence of 1 in 1500 to 7000 live births. These relatively rare disorders are seldom considered when evaluating a sick newborn. A significant number of the >50 different lysosomal storage disorders, however, do manifest in the neonatal period and should be part of the differential diagnosis of several perinatal phenotypes. We review the earliest clinical features, diagnostic tests, and treatment options for lysosomal storage disorders that can present in the newborn. Although many of the lysosomal storage disorders are characterized by a range in phenotypes, the focus of this review is on the specific symptoms and clinical findings that present in the perinatal period, including neurologic, respiratory, endocrine, and cardiovascular manifestations, dysmorphic features, hepatosplenomegaly, skin or ocular involvement, and hydrops fetalis/congenital ascites. A greater awareness of these features may help to reduce misdiagnosis and promote the early detection of lysosomal storage disorders. Implementing therapy at the earliest stage possible is crucial for several of the lysosomal storage disorders; hence, an early appreciation of these disorders by physicians who treat newborns is essential.

摘要

溶酶体贮积症是罕见的先天性代谢缺陷病,活产婴儿中的合并发病率为1/1500至1/7000。在评估患病新生儿时,这些相对罕见的疾病很少被考虑。然而,超过50种不同的溶酶体贮积症中有相当一部分在新生儿期就会出现症状,应作为几种围产期表型鉴别诊断的一部分。我们回顾了新生儿期可能出现的溶酶体贮积症的最早临床特征、诊断测试和治疗选择。虽然许多溶酶体贮积症具有多种表型,但本综述的重点是围产期出现的特定症状和临床发现,包括神经、呼吸、内分泌和心血管表现、畸形特征、肝脾肿大、皮肤或眼部受累以及胎儿水肿/先天性腹水。对这些特征有更多的认识可能有助于减少误诊并促进溶酶体贮积症的早期发现。对于几种溶酶体贮积症来说,尽早实施治疗至关重要;因此,治疗新生儿的医生尽早认识这些疾病至关重要。

相似文献

1
Lysosomal storage disorders in the newborn.新生儿溶酶体贮积症
Pediatrics. 2009 Apr;123(4):1191-207. doi: 10.1542/peds.2008-0635.
2
Hydrops fetalis: lysosomal storage disorders in extremis.胎儿水肿:极端情况下的溶酶体贮积症。
Adv Pediatr. 1999;46:409-40.
3
Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.非免疫性胎儿水肿中的溶酶体贮积病谱:一项回顾性病例对照研究
Prenat Diagn. 2020 May;40(6):738-745. doi: 10.1002/pd.5678. Epub 2020 Mar 20.
4
Perinatal-lethal Gaucher disease presenting as hydrops fetalis.表现为胎儿水肿的围产期致死性戈谢病。
Pan Afr Med J. 2015 Jun 10;21:110. doi: 10.11604/pamj.2015.21.110.7052. eCollection 2015.
5
[Hydrops fetalis as an indication for a systematic investigation into the presence of lysosomal storage diseases].胎儿水肿作为对溶酶体贮积病存在情况进行系统调查的指征
Ned Tijdschr Geneeskd. 2004 Feb 7;148(6):264-8.
6
Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease.胎儿水肿:在包括法伯病在内的溶酶体贮积病中的表现。
Eur J Pediatr. 1997 Apr;156(4):292-5. doi: 10.1007/s004310050603.
7
Lysosomal storage disorders as an etiology of nonimmune hydrops fetalis: A systematic review.溶酶体贮积症致非免疫性胎儿水肿的病因学:系统评价。
Clin Genet. 2021 Nov;100(5):493-503. doi: 10.1111/cge.14005. Epub 2021 Jul 16.
8
Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly.溶酶体贮积症作为肝脾肿大的鉴别诊断。
Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):619-28. doi: 10.1016/j.bpg.2010.09.001.
9
Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis.非免疫性胎儿水肿中溶酶体疾病的快速诊断方案。
Prenat Diagn. 2012 Dec;32(12):1139-42. doi: 10.1002/pd.3972. Epub 2012 Sep 18.
10
Prenatal diagnosis of lysosomal storage diseases using fetal blood.利用胎儿血液进行溶酶体贮积病的产前诊断。
Prenat Diagn. 1999 Oct;19(10):930-3. doi: 10.1002/(sici)1097-0223(199910)19:10<930::aid-pd664>3.0.co;2-x.

引用本文的文献

1
Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease.泰-萨克斯病的诊断进展、病理机制、临床影响及未来治疗前景
Neurol Int. 2025 Jun 25;17(7):98. doi: 10.3390/neurolint17070098.
2
Lysosomal storage disorders in nonimmune hydrops fetalis diagnosed by exome sequencing.通过外显子组测序诊断非免疫性胎儿水肿中的溶酶体贮积症。
Orphanet J Rare Dis. 2025 Jul 10;20(1):351. doi: 10.1186/s13023-025-03851-9.
3
Human-based complex models: their promise and potential for rare disease therapeutics.基于人类的复杂模型:它们在罕见病治疗中的前景与潜力。
Front Cell Dev Biol. 2025 Jan 27;13:1526306. doi: 10.3389/fcell.2025.1526306. eCollection 2025.
4
Lysosomal storage disorders: from biology to the clinic with reference to India.溶酶体贮积症:结合印度情况从生物学进展到临床应用
Lancet Reg Health Southeast Asia. 2022 Nov 21;9:100108. doi: 10.1016/j.lansea.2022.100108. eCollection 2023 Feb.
5
Characterization of pregnancy outcome of women with an offspring with inborn errors of metabolism: A population-based study.患有代谢性先天性疾病子女的妇女的妊娠结局特征:一项基于人群的研究。
Front Genet. 2022 Nov 9;13:1030361. doi: 10.3389/fgene.2022.1030361. eCollection 2022.
6
Parental Depression and Anxiety Associated with Newborn Bloodspot Screening for Rare and Variable-Onset Disorders.与新生儿罕见和迟发性疾病血斑筛查相关的父母抑郁和焦虑
Int J Neonatal Screen. 2022 Nov 10;8(4):59. doi: 10.3390/ijns8040059.
7
Natural history and management of liver dysfunction in lysosomal storage disorders.溶酶体贮积症中肝功能障碍的自然史与管理
World J Hepatol. 2022 Oct 27;14(10):1844-1861. doi: 10.4254/wjh.v14.i10.1844.
8
Comparative Proteomic Assessment of Normal vs. Polyhydramnios Amniotic Fluid Based on Computational Analysis.基于计算分析的正常与羊水过多羊水的比较蛋白质组学评估
Biomedicines. 2022 Jul 28;10(8):1821. doi: 10.3390/biomedicines10081821.
9
Ascites in infantile onset type II Sialidosis.婴儿期发病的II型唾液酸贮积症中的腹水。
JIMD Rep. 2022 Jun 3;63(4):316-321. doi: 10.1002/jmd2.12305. eCollection 2022 Jul.
10
A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation.两名患有新突变的戈谢病2型患者中胎儿水肿的罕见病因。
Metab Brain Dis. 2022 Apr;37(4):1283-1287. doi: 10.1007/s11011-022-00942-5. Epub 2022 Mar 7.

本文引用的文献

1
Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.法布里病的活性位点特异性伴侣蛋白疗法。酶抑制剂的阴阳之道。
FEBS J. 2007 Oct;274(19):4962-71. doi: 10.1111/j.1742-4658.2007.06041.x.
2
Pharmacologic chaperoning as a strategy to treat Gaucher disease.药物伴侣疗法作为治疗戈谢病的一种策略。
FEBS J. 2007 Oct;274(19):4944-50. doi: 10.1111/j.1742-4658.2007.06042.x.
3
Hematopoietic cell therapy for metabolic disease.用于代谢性疾病的造血细胞疗法。
J Pediatr. 2007 Oct;151(4):340-6. doi: 10.1016/j.jpeds.2007.04.054.
4
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.通过定量高通量筛选鉴定出的三类葡萄糖脑苷脂酶抑制剂是戈谢病的伴侣型先导化合物。
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13192-7. doi: 10.1073/pnas.0705637104. Epub 2007 Aug 1.
5
Gaucher disease.戈谢病
Curr Opin Chem Biol. 2007 Aug;11(4):412-8. doi: 10.1016/j.cbpa.2007.05.035. Epub 2007 Jul 23.
6
Novel therapeutic targets for the treatment of Fabry disease.治疗法布里病的新型治疗靶点。
Expert Opin Ther Targets. 2007 Jun;11(6):821-33. doi: 10.1517/14728222.11.6.821.
7
PCR-based restriction fragment length polymorphism and haplotype of the most common mutation L176F in the beta-glucuronidase gene.基于聚合酶链反应的β-葡萄糖醛酸酶基因最常见突变L176F的限制性片段长度多态性和单倍型
Genet Test. 2007 Spring;11(1):72-4. doi: 10.1089/gte.2006.0505.
8
High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.用于筛选作为药理伴侣的人溶酶体β-N-乙酰己糖胺酶抑制剂的高通量筛选。
Chem Biol. 2007 Feb;14(2):153-64. doi: 10.1016/j.chembiol.2006.12.006.
9
Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders.使用小分子治疗糖脂溶酶体贮积症的药物治疗策略。
Expert Opin Pharmacother. 2007 Mar;8(4):427-35. doi: 10.1517/14656566.8.4.427.
10
Short femurs detected at 25 and 31 weeks of gestation diagnosed as Leroy I-cell disease in the postnatal period: a report of two cases.孕25周和31周时检测到股骨短小,出生后诊断为勒罗伊I细胞病:两例报告。
Fetal Diagn Ther. 2007;22(3):198-202. doi: 10.1159/000098717. Epub 2007 Jan 17.